Sarah Romano is CFO at EYEGATE PHARMACEUTICALS INC (EYEG). They have made 11 open-market trades across 3 companies since 2017, most recently 2025-01-06.
CIK 0001697536
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $10K since 2017, against 10 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ENTO | SELL | 2025-01-06 | 2025-01-08 | $0.64 | $465 | N/A | N/A | N/A |
| ENTO | SELL | 2024-10-09 | 2024-10-10 | $0.45 | $214 | N/A | N/A | N/A |
| ENTO | SELL | 2024-07-02 | 2024-07-03 | $1.07 | $664 | N/A | N/A | N/A |
| FWBI | SELL | 2024-04-01 | 2024-04-03 | $4.23 | $317 | N/A | N/A | N/A |
| FWBI | SELL | 2024-03-15 | 2024-03-19 | $4.96 | $6K | N/A | N/A | N/A |
| FWBI | SELL | 2024-01-12 | 2024-01-17 | $4.20 | $412 | N/A | N/A | N/A |
| FWBI | SELL | 2023-10-04 | 2023-10-06 | $0.29 | $486 | N/A | N/A | N/A |
| FWBI | SELL | 2023-07-03 | 2023-07-05 | $1.54 | $3K | N/A | N/A | N/A |
| FWBI | SELL | 2023-04-03 | 2023-04-05 | $2.50 | $5K | N/A | N/A | N/A |
| EYEG | SELL | 2019-07-11 | 2019-07-15 | $0.24 | $9K | -9.9% | -15.5% | +0.7% |
| EYEG | BUY | 2017-08-15 | 2017-08-17 | $1.00 | $10K | +10.8% | +23.7% | +17.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.